

*Date:* February 13, 2017.

*Time:* 12:01 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Ave., Bethesda, MD 20892.

*Contact Person:* Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Room 2C218, Bethesda, MD 20892, 301-496-9374, [grimaldim2@mail.nih.gov](mailto:grimaldim2@mail.nih.gov).

*Name of Committee:* National Institute on Aging Special Emphasis Panel; 2017 Beeson Review.

*Date:* February 24, 2017.

*Time:* 11:00 a.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Alexander Parsadonian, Ph.D., Scientific Review Officer, National Institute on Aging, Gateway Building 2C/212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-496-9666, [Parsadonian@nia.nih.gov](mailto:Parsadonian@nia.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: December 23, 2016.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-31566 Filed 12-28-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive Patent License: Development and Commercialization of Nitrite Salts for the Treatment, Amelioration, and Prevention by Any Route of Administration of Pulmonary Hypertension, Including All WHO Classifications of Pulmonary Hypertension, e.g., Groups 1-5

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Heart, Lung, and Blood Institute ("NHLBI"), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to United Therapeutics Corporation ("United") located in Silver Spring, MD

and incorporated under the laws of Delaware.

**DATES:** Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before January 13, 2017 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated exclusive license should be directed to: Cristina Thalhammer-Reyero, Ph.D., MBA, Senior Licensing and Patenting Manager, NHLBI Office of Technology Transfer and Development, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; Telephone: +1-301-435-4507; Fax: +1-301-594-3080; Email: [thalhamc@mail.nih.gov](mailto:thalhamc@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** The following represents the intellectual property to be licensed under the prospective agreement:

PCT Application Number: PCT/US2004/21985, filed 9 July 2004, and corresponding US, EP, CA, AU and JP filings; and PCT Patent Application PCT/US2004/22232 filed 9 July 2004, and corresponding issued patents in EP, CA, AU and JP, as well as US 8,927,030 issued 01/06/2015; US 9,387,224 issued 07/12/2016, and two pending US patent applications; Titled "Use of Nitrite Salts for the treatment of Cardiovascular Conditions" (NIH Reference No. E-254-2003/0,1,2,3)

With respect to persons who have an obligation to assign their right, title and interest to the Government of the United States of America, the patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to: "Use of the Licensed Patent Rights for the treatment, amelioration, and prevention of any kind or nature and by any route of administration of Pulmonary Hypertension, including all WHO classifications of pulmonary hypertension, e.g., Groups 1-5".

The invention pertains to the unexpected finding that low, physiological and non-toxic concentrations of sodium nitrite are able to increase blood flow and produce vasodilation by infused and nebulized routes of administration.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective Exclusive Patent License will be royalty bearing and may be granted unless within fifteen (15) days from the date of this published notice, the NHLBI Office of Technology

Transfer and Development receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated Exclusive Patent License. Comments and objections to this notice submitted will not be made available for public inspection and, to the extent permitted by law, will not be released under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: December 21, 2016.

**Cristina Thalhammer-Reyero,**

*Senior Licensing and Patenting Manager, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute.*

[FR Doc. 2016-31437 Filed 12-28-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary and Integrative Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council for Complementary and Integrative Health.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Complementary and Integrative Health.

*Date:* February 3, 2017.

*Closed:* 8:30 a.m. to 9:15 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.

*Open:* 9:30 a.m. to 3:15 p.m.

*Agenda:* A report from the Institute Director and other staff.

*Place:* National Institutes of Health, Building 31, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.

*Contact Person:* Martin H. Goldrosen, Ph.D., Director, Division of Extramural Activities, National Center for Complementary and Integrative Health, NIH, 6707 Democracy Blvd., Ste. 401, Bethesda, MD 20892-5475, (301) 594-2014, [goldrosm@mail.nih.gov](mailto:goldrosm@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <https://nccih.nih.gov/about/naccih/>, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Integrative Health, National Institutes of Health, HHS)

Dated: December 22, 2016.

**Michelle Trout,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-31430 Filed 12-28-16; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy And Infectious Diseases; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting.

*Date:* January 11-12, 2017.

*Time:* 7:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Hilton Garden Inn Savannah Historic District, Telfair Conference Room, 321 West Bay Street, Savannah, GA 31401.

*Contact Person:* Ellen S. Buczko, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3F30A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5028, [ebuczko1@niaid.nih.gov](mailto:ebuczko1@niaid.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01).

*Date:* January 25-26, 2017.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 3G53, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Julio Aliberti, Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9823, Rockville, MD 20852, 301-761-7322, [alibertijc@niaid.nih.gov](mailto:alibertijc@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: December 23, 2016.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-31610 Filed 12-28-16; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Using Informatics To Improve Data Analysis of Chemical Screening Assays Conducted in Zebrafish; Notice of Webinars; Registration Information**

**SUMMARY:** The National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences announces the webinar series, "Using Informatics to Improve Data Analysis of Chemical Screening Assays Conducted in Zebrafish." The webinars will

provide an overview of current issues that need to be addressed to facilitate the broader use of zebrafish for chemical safety screening studies and how data science can be applied to address some of those issues.

**DATES:** *First Webinar:* February 2, 2017, from 11:30 a.m. to 1:00 p.m. Eastern Standard Time (EST).

*Subsequent Webinars:* February 16, 2017; March 2, 2017; both webinars will be presented from 11:30 a.m. to 12:30 p.m. EST.

*Registration for Webinars:* Registration will be open continuously; registration for any webinar will automatically register the participant for all subsequent webinars.

**ADDRESSES:** *Web page:* The preliminary agenda, registration, and other meeting materials are at <http://ntp.niehs.nih.gov/go/zfweb-2017>.

**FOR FURTHER INFORMATION CONTACT:** Dr. Elizabeth Maull, NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), at telephone: (919) 316-4668 or email: [maull@niehs.nih.gov](mailto:maull@niehs.nih.gov).

**SUPPLEMENTARY INFORMATION:**

*Background:* The small size and rapid development of the zebrafish make it a useful vertebrate model for assessing potential effects of chemicals on development in a medium to high-throughput manner. However, a lack of harmonization in several key protocol components hinders the broader adoption of the zebrafish model for toxicological screening. In an effort to address this issue, NTP launched the Systematic Evaluation of the Application of Zebrafish in Toxicology (SEAZIT) program.

SEAZIT is addressing the issues of variability among laboratories in the endpoints measured, as well as the nomenclature used for each endpoint. NICEATM is organizing a webinar series in support of the SEAZIT program that will consider how these issues might be addressed by implementation of standardized nomenclature systems, also known as ontologies.

Webinars in this series will (1) summarize some of the barriers to routine use of zebrafish in toxicological evaluations, (2) review the concept of ontologies, and (3) consider how ontologies could be applied to harmonize procedures used for zebrafish screening studies.

*Webinar Topics and Other Information:* A link to registration and additional information about the webinar series, including topics and speakers for all webinars, are available at <http://ntp.niehs.nih.gov/go/zfweb-2017>. The webinar steering committee is